Bavarian Nordic A/S
Bavarian Nordic A/S
Your view on BVNRY
Overview
What the company does, where it operates, and who runs it.
About Bavarian Nordic A/S
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Paul John Chaplin
- Headquarters
- Philip Heymans Alle 3, Hellerup, DK
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Paul John Chaplin
- Headquarters
- Philip Heymans Alle 3, Hellerup, DK
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines.
The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.
It is also developing MVA-BN (freeze-dried) that has completed Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase II clinical trial for the treatment of SARS-CoV-2; and TAEK-VAC, which is in Phase I/II clinical trial for treatment of advanced HER2 and brachyury-expressing cancers.
It has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, Belgium, Germany, the Netherlands, Sweden, Switzerland, Austria, the United Kingdom, Japan, and internationally.
Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Bavarian Nordic A/S, and the rating behind it. BVNRY last traded at $10.29, 10.3× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Bavarian Nordic A/S. Starting points for Bavarian Nordic A/S: P/E 10.3, EPS $6.77, beta 1.13 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Bavarian Nordic A/S. Bavarian Nordic A/S does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Bavarian Nordic A/S. Trailing twelve-month EPS for Bavarian Nordic A/S stands at $6.77. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Bavarian Nordic A/S. Bavarian Nordic A/S has reported as a listed company since 2013. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Bavarian Nordic A/S valued side by side against its closest peers. Bavarian Nordic A/S is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Bavarian Nordic A/S, and how their positions are changing. At a $2.42B market value, institutional positions materially move Bavarian Nordic A/S's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Bavarian Nordic A/S executives and directors. Shares of Bavarian Nordic A/S have traded between $6.59 and $13.00 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Bavarian Nordic A/S. Bavarian Nordic A/S is a $2.42B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Bavarian Nordic A/S. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Bavarian Nordic A/S. Coverage tracks Bavarian Nordic A/S within Biotechnology (Healthcare). Press releases and market coverage, newest first.